検索
Inhibikase Therapeutics Inc
IKTウォッチリストに追加
2.100USD
-0.050-2.33%
終値 09-24 16:00（ET）
329.76M時価総額
損失額直近12ヶ月PER
Inhibikase Therapeutics Incについて 企業名
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).
Inhibikase Therapeutics Inc プロフィール
企業コードIKT
会社名Inhibikase Therapeutics Inc
上場日Dec 23, 2020
最高経営責任者「CEO」Iwicki (Mark T)
従業員数15
証券種類Ordinary Share
決算期末Dec 23
本社所在地1000 N. West Street, Suite 1200
都市WILMINGTON
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号19801
電話番号13022953800
ウェブサイトhttps://www.inhibikase.com/
企業コードIKT
上場日Dec 23, 2020
最高経営責任者「CEO」Iwicki (Mark T)
Inhibikase Therapeutics Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
President, Head - Research and Development
President, Head - Research and Development
676.56K
--
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
President, Head - Research and Development
President, Head - Research and Development
676.56K
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
510.60K
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
510.60K
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
403.18K
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
403.18K
--
Mr. Arvind Kush
Mr. Arvind Kush
Independent Director
Independent Director
145.00K
--
Mr. Arvind Kush
Mr. Arvind Kush
Independent Director
Independent Director
145.00K
--
Mr. Dennis N. Berman
Mr. Dennis N. Berman
Independent Director
Independent Director
21.85K
--
Mr. Dennis N. Berman
Mr. Dennis N. Berman
Independent Director
Independent Director
21.85K
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
President, Head - Research and Development
President, Head - Research and Development
676.56K
--
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
President, Head - Research and Development
President, Head - Research and Development
676.56K
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
510.60K
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
510.60K
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
403.18K
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
403.18K
--
よくある質問
Inhibikase Therapeutics Incの上位5名の株主は誰ですか？
Inhibikase Therapeutics Incの上位5名の株主は以下のとおりです。Dr. Christopher H. (Chris) Cabell, M.D.
Inhibikase Therapeutics Inc（IKT）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Inhibikase Therapeutics Incの株式を保有している機関は152社あり、保有株式の総市場価値は約103.21Mで、全体の78.17%を占めています。2025Q4と比較して、機関の持ち株は43845693.00増加しています。